RFA
PBE icon

Reilly Financial Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Reilly Financial Advisors’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-300
Closed -$11K – 928
2016
Q1 		$11K Hold
300
– – ﹤0.01% 739
2015
Q4 		$15K Buy
+300
New +$14.8K ﹤0.01% 676

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AWA
Artemis Wealth Advisors New York $662M AUM 39.67% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PA
PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

Reilly Financial Advisors's PBE Position: Q4 2021 in Review

Reilly Financial Advisors held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q4 2021 at 300 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #567.

Reilly Financial Advisors first reported a position in PBE in Q4 2013 and has held it in 31 quarters since. The position peaked at $33K in Q1 2015. 101 funds tracked by Wall St. Rank hold PBE as of Q4 2021.

  • Reilly Financial Advisors held 300 shares of Invesco Biotechnology & Genome ETF worth $21K as of Q4 2021.
  • Reilly Financial Advisors left its Invesco Biotechnology & Genome ETF share count unchanged in Q4 2021.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Reilly Financial Advisors's portfolio in Q4 2021, its #567 holding.
  • Reilly Financial Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q4 2013 and has held it in 31 quarters since.
  • Reilly Financial Advisors's Invesco Biotechnology & Genome ETF position peaked at $33K in Q1 2015.
  • 101 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2021.

Based on Reilly Financial Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.